Pomp Investments investor Anthony Pompliano discusses the likelihood of a Bitcoin boom on 'The Claman Countdown.' The ...

Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...

AbbVie (ABBV) shares dip for 7th day, but analysts see buying opportunity after recent setback in schizophrenia drug trials.

Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

“The drug discovery process is long, inefficient and costly, with the majority of new drugs failing during clinical trials,” ...

NORTH CHICAGO, Ill. - AbbVie Inc . (NYSE: NYSE:ABBV) disclosed today that its board of directors has declared a quarterly cash dividend. The payment, set at $1.55 per share, is... ByInvesting.com ...

SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.

Akamine joins Kailera from Cerevel Therapeutics where he served as chief legal officer and corporate secretary until the ...

In August, nurses went on a seven-day strike but were unsuccessful in reaching an agreement for a new contract. Now they say ...